The analyses carried out using two different bioinformatics pipelines (SomaticSniper and MuTect) on the same set of genomic data from 133 Acute Myeloid Leukemia (AML) patients, sequenced inside the Cancer Genome Atlas project, gave discrepant results. We subsequently tested these two variant-calling pipelines on 20 leukemia samples from our series (19 primary AMLs and one secondary AML). By validating many of the predicted somatic variants (variant allele frequencies ranging from 100% to 5%), we observed significantly different calling efficiencies. In particular, despite relatively high specificity, sensitivity was poor in both pipelines resulting in a high rate of false negatives. Our findings raise the possibility that landscapes of AML genomes might be more complex than previously reported and characterized by the presence of hundreds of genes mutated at low variant allele frequency, suggesting that the application of genome sequencing to the clinic requires a careful and critical evaluation. We think that improvements in technology and workflow standardization, through the generation of clear experimental and bioinformatics guidelines, are fundamental to translate the use of Next generation sequencing from research to the clinic and to transform genomic information into better diagnosis and outcomes for the patient.
Introduction
Whole genome sequencing (WGS) and whole exome sequencing (WES) are widely used for mutational analysis in cancer samples. These new technologies are changing our understanding of the genomic landscape of cancer, including Acute Myeloid Leukemia (AML). Indeed, in the last few years WGS and WES have allowed the identification of key mutated genes in AML, such as DNMT3A 1 For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From
In order to assess the quality of a statistical approach, the identified mutations are usually validated by an independent method, evaluating the percentage of false positives (specificity analysis). The evaluation of false negatives (sensitivity analysis), instead, is more difficult, as true somatic mutations in a given sample are for the most part unknown. Thus, the fraction of true mutations missed in an analysis is generally undetermined.
Moreover, one of the main challenges in analyzing WES and WGS data is the identification of somatic variants present at low frequency (under 10%), as they are more difficult to distinguish from sequencing errors. Low-frequency mutations may also occur due to the presence, in the tumor sample, of highly variable percentages of normal cells or multiple tumor clones, whose relative representation might also vary greatly 5 . Since the detection of rare variants mainly depends on sequence coverage, this problem is even worsened in WGS studies, which usually have lower coverage than WES studies. Figure 1A ). In addition, the percentages of the possible base changes are surprisingly different between the outputs of the two methods ( Figure 1B and Supplementary For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From and RASA1. These genes encode for proteins involved in the regulation of cell proliferation or differentiation and are thus relevant for cancer progression. Finally, the identified SNVs can partly explain the hypermutated phenotype observed in some patients. Indeed, we have identified non silent SNVs in mismatch repair genes in 3 out of 7 hypermutated patients: in the MSH6 gene in two patients and in the PMS1 gene in a third patient. However, our analysis is restricted to SNVs, so we cannot exclude the presence of additional mutations as indels or structural variants in mismatch repair genes in the remaining patients that could explain hypermutation.
Comparison and validation of the two bioinformatics pipelines
To investigate their performances, we compared the behavior of SomaticSniper and MuTect on 20 leukemia samples from our series (19 primary AMLs, including 8
Acute Promyelocytic Leukemias, APLs, and one secondary APL) 13 . All cases were analyzed by WES (Supplementary Table 3 (Table 1) . Strikingly, the overall validation rate was extremely high (89% corresponding to 84/94 validated SomaticSniper SNVs and 98% corresponding to 95/97 validated MuTect SNVs), unveiling that a significant number of mutations are missed by one pipeline and identified by the other, or viceversa. Thus, when we examine the calling of SNVs at >10% frequency, the ability to minimize false positives is extremely good with both pipelines. On the other hand, the ability of the two pipelines to minimize false negatives appears relatively poor, with a minimum of 84 missed SNVs with SomaticSniper and of 33 with MuTect.
As mentioned, MuTect also allows identification of SNVs with a low variant allele frequency, up to the limit of 2% in our analyses. Indeed, it identified 218 SNVs with a frequency between 10 and 2% in our 20 AML samples (~12/patient; Table 1 ). 48/60 (~80%) of these SNVs were validated in the same DNAs, using semiconductor sequencing with the Ion Torrent Personal Genome Machine and Illumina MiSeq Sequencing System. As the detection threshold of the Sanger technology, under our experimental conditions, exceeds ~25% (unpublished), we decided to use both the Ion Table 5 ). We know from the literature that both TET2 and DNMT3A play a key role in leukemia development 16 , and can be present at low-frequency in the remission sample (especially DNMT3A), representing a typical case of contamination of the normal sample with residual tumor cells. These results underline the need to be aware of possible sources of contamination derived by minimal residual disease in normal samples, which can greatly challenge the efficiency of bioinformatics pipelines in SNV-calling, as previously described 14 . This is a particularly important issue for leukemic samples, for which the normal sample is usually represented by the remission sample (as in our study) and might be contaminated, depending on the patient, with different percentages of the tumor DNA.
Furthermore, we also observed some differences in the VAFs of mutations identified only by SomaticSniper and the VAFs for the same positions estimated by MuTect (Supplementary Figure 3) . This might be due to the fact that the two pipelines employ different approaches to filter the reads used in the mutation calling phase. MuTect, for example, is more lenient in filtering reads in the normal sample than in the tumor
For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From sample, resulting in an augmented strictness in calling mutations which are present at low allelic frequencies in the normal. SomaticSniper, instead, filters out poor quality reads, both in normal and tumor samples, on the bases of a parameter given by the user. In addition, MuTect does not allow the identification of mutations that differ from the reference genome in the normal sample, although mutated in the tumor sample.
Conclusions
The presence of false negatives in the analysis of both pipelines has important consequences, as this may lead to an undervaluation of the occurrence of somatic mutations in AMLs, which might be critical for the identification of relevant targets, definition of clonality patterns 17 , and identification of prognostic markers, which in turn may impact on therapeutic decisions (actionable mutations 18 ).
Most of our knowledge regarding the genomic landscape of AML comes from the analysis with SomaticSniper of sequencing data of 200 cases of AML 9 . We decided to compare SomaticSniper and MuTect, since these two programs have been used to analyze and characterize the same AML genomes 9, 10 . Our goal was to reconcile the somehow contradictory results obtained analyzing the same set of data with these two techniques and, in particular, to test the putative presence of mutations at low frequency in AML genomes.
Our study raises the possibility that there might be a more complex landscape for AML genomes than previously reported. In addition, though we are unable to tell whether the mutations identified by MuTect in the five samples classified as "hypermutated" are all real or there may be sequencing artifacts, these findings arise new scientific questions on the possible causes that lead some AML samples to be hypermutated, and whether this characteristic is connected to particular clinical features.
However, SomaticSniper and MuTect are only two of the many existing mutation callers. For this reason, our analysis might underestimate the presence of false negatives, as the use of other mutation callers could increase the false negative rate.
The scientific community is becoming increasingly aware of the problems related to Concerning data production, a major issue of standard NGS platforms is the intrinsic error rate (around 1%), too high to allow detection of rare variants. NGS technologies refinement is a possible way to overcome the false negatives problem: for example,
introducing new applications for library preparation, such as the recently published method termed duplex sequencing 19 . By tagging all the reads derived from the same DNA fragment and discarding any change between the two different strands of DNA, this method is reported to reduce the error rate of NGS up to 10 million fold.
Therefore, it might shed some light on very rare variants and enable the identification of false positives and false negatives in cancer genomes, accurately describing the mutational landscape of individual tumors.
Improvement in sequencing technologies, increase in sequence coverage, precise guidelines in mutation calling, and increase in sensitivity will advance our understanding of the clonal substructure of human cancers, allow to revise the catalog of somatic mutation, and help elucidate mechanisms of mutational processes from which it is possible to infer patterns of DNA damage and repair processes 20 .
Conservatively, for now, it is recommended to analyze WES-data with more than one pipeline. We also believe that workflow standardization through the generation of clear bioinformatics guidelines is fundamental to translate the use of NGS from research to the clinics and to transform genomic information into improved diagnosis and treatment.
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